100 results on '"Meiler, Johannes"'
Search Results
2. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
4. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
5. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer
6. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
7. Refraktäre Hodentumore und Rezidive: Therapie
8. Systemische Therapie: Grundlagen
9. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center
10. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
11. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
12. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care—Registry data from an outcomes research project of the German Testicular Cancer Study Group
13. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer
14. Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
15. A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).
16. Abstract P5-11-14: Palbociclib in combination with anastrozole or exemestane as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
17. Perioperative chemotherapy for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
18. A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).
19. Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC).
20. Palbociclib in combination with letrozole as first- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany : Interim results of the INGE-B phase 2 study
21. Evaluation of prognostic markers in patients (pts) with advanced gastric cancer (GC) and adenocarcinoma of the gastroesophageal junction (AEG) treated with systemic chemothearpy (ctx) at the West German Cancer Center
22. Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power)
23. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma : The multicenter, rand
24. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
25. Evaluation of prognostic markers in patients (pts) with metastatic colorectal cancer (mCRC) treated with a bevacizumab (bev) based chemotherapy (ctx) at the West German Cancer Center
26. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
27. Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
28. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
29. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
30. Prognostische Faktoren bei Patienten mit fortgeschrittenen Pankreaskarzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
31. Evaluation of systemic inflammatory response (SIR) markers in advanced biliary tract cancer (ABTC)
32. Prognostische Faktoren bei Patienten mit fortgeschrittenen cholangiozellulären Karzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
33. Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)
34. Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer.
35. Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ)
36. Prognostic factors in patients with pancreatic cancer receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ), one of the 12 Oncology Centers of Excellence in Germany
37. Prognostic factors in patients (pts) with advanced cholangiocellular carcinoma (CCC) receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ)
38. Molecular and clinical predictors of the efficacy of cetuximab in combination with mFOLFOX6 in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC) – subgroup analyses of the CEBIFOX trial
39. WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
40. Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
41. Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies
42. Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ), one of the 11 Oncology Centers of Excellence in Germany
43. Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial.
44. Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.
45. Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
46. LBA-008 - Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
47. Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
48. Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
49. Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
50. Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.